Changes in Prevalence and Incidence of Parkinson’s Disease in Japan during a Quarter of a CenturyYamawaki M. · Kusumi M. · Kowa H. · Nakashima K.
Department of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Yonago, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background/Aim: To determine the prevalence and incidence of Parkinson’s disease (PD) and compare them with results from our previous studies. Methods: We examined epidemiological characteristics of PD patients using a service-based study in Yonago City, and a door-to-door study in Daisen Town. The prevalence days were April 1, 2004 in Yonago, and April 1, 2003 in Daisen. Results: In Yonago, we identified 254 PD patients. The crude prevalence was 180.3 (95% CI, 158.1–202.4) per 100,000 population. The adjusted prevalence was 145.8 (95% CI, 145.2–146.5) in 1980, 147.0 (95% CI, 146.3–147.6) in 1992, and 166.8 (95% CI, 166.1–167.5) in 2004, when calculated using the Japanese population in 2004. The crude incidence was 18.4 (95% CI, 11.3–25.5) per 100,000 population per year. The crude incidence in 1980 was 10.2 (95% CI, 4.6–15.8), and the adjusted incidence was 9.8 (95% CI, 4.3–15.3) in 1992, and 10.3 (95% CI, 4.7–15.9) in 2004, when calculated using the population in Yonago in 1980. In Daisen, there were 21 PD patients. The crude prevalence was 306.6 (95% CI, 175.7–437.6) and the adjusted prevalence was 192.6 (95% CI, 191.9–193.8). Conclusions: The prevalence of PD had increased, primarily because the population had aged. Differences in prevalence between these adjacent areas may have resulted from differences in the methods of investigation.
© 2009 S. Karger AG, Basel
- Harada H, Nishikawa S, Takahashi K: Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol 1983;40:151–154.
- Kusumi M, Nakashima K, Harada H, Nakayama H, Takahashi K: Epidemiology of Parkinson’s disease in Yonago City, Japan: comparison with a study carried out 12 years ago. Neuroepidemiology 1996;15:201–207.
- von Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R: Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005;15:473–490.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
- Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.
- Anderson GF, Hussey P: Population aging: a comparison among industrialized countries. Health Aff 2000;19:191–203.
- Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, Huang JB, Zhou B, Geng ZP, Wu JX, Wen HB, Zhao H, Zahner GE: Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 2005;365:595–597.
- Chen RC, Chang SF, Su CL, Chen TH, Yen MF, Wu HM, Chen ZY, Liou HH: Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan county, Taiwan. Neurology 2001;57:1679–1686.
de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A: Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurology 2000;54(suppl 5):S21–S23.
- Chan DK, Cordato D, Karr M, Ong B, Lei H, Liu J, Hung WT: Prevalence of Parkinson’s disease in Sydney. Acta Neurol Scand 2005;111:7–11.
- de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meché FG, Hofman A: Prevalence of Parkinson’s disease in the elderly: the Rotterdam Study. Neurology 1995;45:2143–2146.
- Schrag A, Ben-Shlomo Y, Quinn NP: Cross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in London. BMJ 2000;321:21–22.
- de Lau LM, Breteler MM: Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5:525–535.
- Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S: A meta-analysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology 2000;21:435–440.
- Gorell JM, Peterson EL, Rybicki BA, Johnson CC: Multiple risk factors for Parkinson’s disease. J Neurol Sci 2004;217:169–174.
- Morriwaka F, Tashiro K, Itoh K, Honma S, Okumura H, Kikuchi S, Hamada T, Kaneko S, Kurowaka Y: Prevalence of Parkinson’s disease in Hokkaido, the northernmost island of Japan. Intern Med 1996;35:276–279.
- Kimura H, Kurimura M, Wada M, Kawanami T, Kurita K, Suzuki Y Katagiri T, Daimon M, Kayama T, Kato T: Female preponderance of Parkinson’s disease in Japan. Neuroepidemiology 2002;21:292–296.
- Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, Booij J, Dluzen DE, Horstink M: Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007;78:819–824.
- Nakashima K, Maeda M, Tabata M, Adachi Y, Kusumi M, Ohshiro H: Prognosis of Parkinson’s disease in Japan. Tottori University Parkinson’s Disease Epidemiology (TUPDE) Study Group. Eur Neurol 1997;38(suppl 2): 60–63.
- Tan LC, Venketasubramanian N, Hong CY, Sahadevan S, Chin JJ, Krishnamoorthy ES, Tan AK, Saw SM: Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. Neurology 2004;62:1999–2004.
- de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alpérovitch A, Rocca WA: Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON collaborative study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62:10–15.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.